Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

Andrew Blauvelt, Lawrence J. Green, Mark G. Lebwohl, Paul S. Yamauchi, Tina Lin, Gina Martin, Radhakrishnan Pillai

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion were published.1,2 HP/TAZ lotion was significantly more effective than individual active ingredients or vehicle, based on improvements in Investigator’s Global Assessment (IGA), body surface area (BSA) involvement, and signs and symptoms of psoriasis (erythema, plaque elevation, and scaling) at the target lesion as well as a synergistic benefit over individual active ingredients, and good tolerability.

Original languageEnglish
Pages (from-to)297-299
Number of pages3
JournalJournal of Drugs in Dermatology
Volume18
Issue number3
StatePublished - Mar 2019

Fingerprint

Dive into the research topics of 'Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis'. Together they form a unique fingerprint.

Cite this